Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

被引：263

作者：

Allez, Matthieu ^{[1
,2
]}

Karmiris, Konstantinos ^{[3
]}

Louis, Edouard ^{[4
]}

Van Assche, Gert ^{[5
]}

Ben-Horin, Shomron ^{[6
]}

Klein, Amir ^{[7
]}

Van der Woude, Janneke ^{[8
]}

Baert, Filip ^{[9
]}

Eliakim, Rami ^{[7
]}

Katsanos, Konstantinos ^{[10
]}

Brynskov, Jorn ^{[11
]}

Steinwurz, Flavio ^{[12
]}

Danese, Silvio ^{[13
]}

Vermeire, Severine ^{[5
]}

Teillaud, Jean-Luc ^{[14
,15
]}

Lemann, Marc ^{[1
]}

Chowers, Yehuda ^{[7
]}

机构：

[1] Univ Paris 07, Hop St Louis, APHP, Dept Gastroenterol, F-75010 Paris, France

[2] INSERM, U940, Equipe Avenir, F-75654 Paris 13, France

[3] Venizele Gen Hosp, Iraklion, Crete, Greece

[4] Univ Liege, CHU Liege, Dept Gastroenterol, B-4000 Liege, Belgium

[5] Univ Hosp Leuven, Div Gastroenterol, Louvain, Belgium

[6] Tel Aviv Univ, Sackler Sch Med, Sheba Med Ctr, Tel Aviv, Israel

[7] Technion Israel Inst Technol, Rappoport Sch Med, Dept Gastroenterol, Haifa, Israel

[8] Erasmus MC Univ Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands

[9] H Hart Hosp Roeselare, Roeselare, Belgium

[10] Univ Hosp Ioannina, Dept Internal Med 1, Hepatogastroenterol Unit, Ioannina, Greece

[11] Herlev Hosp, Dept Gastroenterol, Copenhagen, Denmark

[12] Hosp Israelita Albert Einstein, Sao Paulo, Brazil

[13] IRCCS Gastroenterol, Ist Clin Humanitas, Div Gastroenterol, Rozzano, Italy

[14] Univ Paris 06, INSERM, UMR S 872, Ctr Rech Cordeliers, Paris, France

[15] Univ Paris 05, Paris, France

来源：

JOURNAL OF CROHNS & COLITIS | 2010年 / 4卷 / 04期

关键词：

Inflammatory bowel diseases; Crohn's disease; Ulcerative colitis; Anti-TNF therapy; Immunogenicity; Pharmacology; ANTITUMOR NECROSIS FACTOR; FISTULIZING CROHNS-DISEASE; INFLIXIMAB DOSE INTENSIFICATION; SCHEDULED MAINTENANCE TREATMENT; NEONATAL FC-RECEPTOR; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; FACTOR-ALPHA; CLINICAL-RESPONSE; RANDOMIZED-TRIAL;

D O I：

10.1016/j.crohns.2010.04.004

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The first ECCO pathogenesis workshop focused on anti-TNF therapy failures in inflammatory bowel diseases (IBDs). The overall objective was to better understand and explore primary non response and loss of response to anti-TNF agents in IBD. The outcome of this workshop is presented into two parts. This first section addresses definitions, frequency and pharmacological aspects of anti-TNF therapy failure, including pharmacokinetics of anti-TNF monoclonal antibodies and immune and non-immune mediated clearance of anti-TNF mAbs. The second section concerns the biological roles of TNF and TNF antagonists, including mechanisms of action of anti-TNF agents, and discuss hypothesis regarding their failures and phenomenon of paradoxical inflammation, including the potential role of TNF independent inflammatory pathways. (C) 2010 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

引用

页码：355 / 366

页数：12

共 70 条

[1] Immunogenicity of anti-tumor necrosis factor antibodies - toward improved methods of anti-antibody measurement [J].

Aarden, Lucien ;

Ruuls, Sigrid R. ;

Wolbink, Gertjan .

CURRENT OPINION IN IMMUNOLOGY, 2008, 20 (04) :431-435

[2] Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease [J].

Ainsworth, Mark A. ;

Bendtzen, Klaus ;

Brynskov, Jorn .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (04) :944-948

[3] The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies [J].

Allez, M. ;

Vermeire, S. ;

Mozziconacci, N. ;

Michetti, P. ;

Laharie, D. ;

Louis, E. ;

Bigard, M. -A. ;

Hebuterne, X. ;

Treton, X. ;

Kohn, A. ;

Marteau, P. ;

Cortot, A. ;

Nichita, C. ;

van Assche, G. ;

Rutgeerts, P. ;

Lemann, M. ;

Colombel, J. -F. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 31 (01) :92-101

[4] Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].

Baert, F ;

Noman, M ;

Vermeire, S ;

Van Assche, G ;

D'Haens, G ;

Carbonez, A ;

Rutgeerts, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608

[5] Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis [J].

Bartelds, Geertje M. ;

Wijbrandts, Carla A. ;

Nurmohamed, Michael T. ;

Stapel, Steven ;

Lems, Willem F. ;

Aarden, Lucien ;

Dijkmans, Ben A. C. ;

Tak, Paul Peter ;

Wolbink, Gerrit Jan .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (07) :921-926

[6] Immunogenicity, efficacy and adverse events of adalimumab in RA patients [J].

Bender, Niko K. ;

Heilig, Christoph E. ;

Droell, Benjamin ;

Wohlgemuth, Jessica ;

Armbruster, Franz-Paul ;

Heilig, Bernhard .

RHEUMATOLOGY INTERNATIONAL, 2007, 27 (03) :269-274

[7]

BENDTZEN K, 2009, SCAND J GASTROENTERO, V13, P1

[8] Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab [J].

Bendtzen, Klaus ;

Geborek, Pierre ;

Svenson, Morten ;

Larsson, Lotta ;

Kapetanovic, Meliha C. ;

Saxne, Tore .

ARTHRITIS AND RHEUMATISM, 2006, 54 (12) :3782-3789

[9] Adalimumab-induced asthma [J].

Bennett, AN ;

Wong, M ;

Zain, A ;

Panayi, G ;

Kirkham, B .

RHEUMATOLOGY, 2005, 44 (09) :1199-1200

[10] TRANSMISSION OF IMMUNITY FROM MOTHER TO YOUNG AND CATABOLISM OF IMMUNOGLOBULINS [J].

BRAMBELL, FW .

LANCET, 1966, 2 (7473) :1087-&

← 1 2 3 4 5 6 7 →